Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, and Bill Sarraille, a partner with Sidley law, speak with Michael Harris, Mercalis’s VP of Patient Support Services Strategy, on the litigation brought by the HIV+Hepatitis Policy Institute against a federal government rule allowing insurers to not count copay assistance toward patient costs. The Court ruled in favor of patients but the government appealed and is refusing to enforce the Court’s ruling.
Carl Schmid provides an update to the NAIC on copay accumulator litigation, including the government’s recent move to appeal and seek clarification from the court and the need for state and federal enforcement that copay assistance, in most instances, must count.
Carl Schmid discusses how the district court decision that HHS must require insurers to count copay assistance towards patient out-of-pocket costs helps to make prescription drugs more affordable and accessible for patients.
Carl Schmid discusses litigation victory for patients brought by the HIV+Hepatitis Policy Institute and diabetes groups in which the judge struck down the federal rule allowing insurers to not count copay assistance toward patient out-of-pocket costs.
Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, is excited about the new Eliminate Hepatitis C (HCV) program put forth by the Biden Administration and being led by former NIH Director Francis Collins, MD, PhD, who is serving as a scientific advisor to the Biden Administration. “This is something we have been asking for years…We know we can end hepatitis C,” Schmid stated.